Genfit S.A. ADR (GNFT)

$4.85 +0.12 (2.54%)
Market Cap 242.62M
Revenue (ttm) 76.76M
Net Income (ttm) 1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 2.12%
Debt to Equity Ratio 0.14
Volume 56,900
Avg Vol 11,412
Day's Range N/A - N/A
Shares Out 50.03M
Stochastic %K 93%
Beta 1.09
Analysts Strong Sell
Price Target $7.50

Company Profile

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 20 16 40 00
Fax: 33 2 20 16 40 01
Address:
Parc EurasantE, 885, avenue EugEne AvinEe, Loos, France
Rickycello
Rickycello Feb. 25 at 12:10 PM
$GNFT bear: 6.78€ base: 10.26€ bull: 15€ Intrinsic value: 3.93€ Sell price target: 10.51€ (12% margin) Reward / risk: 0.39 Risk / reward: 2.54
0 · Reply
Alexis348
Alexis348 Feb. 24 at 6:33 PM
$GNFT what's everyones thought on this. How far up can it go?!
0 · Reply
RunnerSignals
RunnerSignals Feb. 24 at 3:04 PM
Top Stocks Hitting 52-Week High $AXTI $IPG $GNFT $TSM $FRO
0 · Reply
Noobnr1
Noobnr1 Feb. 20 at 12:49 PM
$GNFT 🚀🚀🚀
0 · Reply
FloatSearcher
FloatSearcher Feb. 18 at 9:32 AM
$GNFT Oncology biotech where trial design credibility matters.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 11:31 AM
$GNFT RSI: 54.52, MACD: 0.2324 Vol: 0.24, MA20: 6.04, MA50: 5.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ThunderTheater
ThunderTheater Dec. 26 at 5:29 PM
$GNFT Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Execution quality will determine whether momentum is sustainable.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 11:50 AM
$GNFT Current Stock Price: $0.00
0 · Reply
QuestCube
QuestCube Dec. 26 at 5:35 AM
$GNFT Upside exists, but only alongside disciplined prioritization and resource control. Cash generation will determine how self-sustaining growth becomes. If milestones track on schedule, sentiment can re-rate faster than fundamentals. Future returns will be dictated by execution quality, not headlines.
0 · Reply
judgeyoung2
judgeyoung2 Dec. 3 at 4:29 PM
$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.
0 · Reply
Latest News on GNFT
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

Mar 9, 2026, 1:00 PM EDT - 23 hours ago

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales

Feb 12, 2026, 12:35 PM EST - 25 days ago

GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales

GENFIT Announces 2026 Financial Calendar

Jan 7, 2026, 12:00 PM EST - 2 months ago

GENFIT Announces 2026 Financial Calendar

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy

Dec 10, 2025, 12:00 PM EST - 3 months ago

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy

GENFIT Announces Appointment of new Chief Medical Officer

Nov 27, 2025, 12:00 PM EST - 3 months ago

GENFIT Announces Appointment of new Chief Medical Officer

GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update

Nov 20, 2025, 12:10 PM EST - 3 months ago

GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update

GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Nov 20, 2025, 12:00 PM EST - 3 months ago

GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

Nov 10, 2025, 1:45 AM EST - 4 months ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025

Nov 10, 2025, 1:30 AM EST - 4 months ago

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025

GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market

Oct 30, 2025, 4:00 PM EDT - 4 months ago

GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market

GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025

Oct 28, 2025, 5:10 PM EDT - 4 months ago

GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

Sep 22, 2025, 4:10 PM EDT - 6 months ago

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD

Sep 19, 2025, 4:10 PM EDT - 6 months ago

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Jul 8, 2025, 4:10 PM EDT - 8 months ago

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

Jun 17, 2025, 2:30 PM EDT - 9 months ago

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2025 Financial Information

May 22, 2025, 4:10 PM EDT - 10 months ago

GENFIT Reports First Quarter 2025 Financial Information

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 20, 2025, 4:10 PM EDT - 10 months ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 14, 2025, 4:10 PM EDT - 10 months ago

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 7, 2025, 4:10 PM EDT - 10 months ago

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

GENFIT to Present Latest ACLF Research at EASL Congress 2025

May 5, 2025, 1:30 AM EDT - 11 months ago

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

Apr 29, 2025, 3:10 PM EDT - 11 months ago

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Apr 28, 2025, 4:10 PM EDT - 11 months ago

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Apr 24, 2025, 4:10 PM EDT - 11 months ago

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

Apr 10, 2025, 6:56 AM EDT - 11 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP EWTX

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Mar 20, 2025, 5:10 PM EDT - 1 year ago

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Mar 10, 2025, 5:10 PM EDT - 1 year ago

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Feb 27, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces Revenues and Cash Position as of December 31, 2024

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

Feb 21, 2025, 2:30 AM EST - 1 year ago

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

Feb 14, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Feb 6, 2025, 4:10 PM EST - 1 year ago

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Jan 30, 2025, 2:40 AM EST - 1 year ago

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

GENFIT Announces 2025 Financial Calendar

Jan 29, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces 2025 Financial Calendar

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Jan 13, 2025, 4:10 PM EST - 1 year ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Nov 13, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Reports Third Quarter 2024 Financial Information

Nov 7, 2024, 4:10 PM EST - 1 year ago

GENFIT Reports Third Quarter 2024 Financial Information

Top 4 Health Care Stocks That May Keep You Up At Night

Sep 24, 2024, 8:51 AM EDT - 1 year ago

Top 4 Health Care Stocks That May Keep You Up At Night

BFRG DOCS GILD

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Sep 23, 2024, 1:30 AM EDT - 1 year ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Jul 26, 2024, 7:45 AM EDT - 1 year ago

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Jun 17, 2024, 4:10 PM EDT - 1 year ago

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Jun 10, 2024, 5:22 PM EDT - 1 year ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

US FDA approves Genfit and Ipsen's liver disease drug

Jun 10, 2024, 5:08 PM EDT - 1 year ago

US FDA approves Genfit and Ipsen's liver disease drug

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

May 29, 2024, 4:10 PM EDT - 1 year ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Genfit: Under The Radar Biotech With Upcoming Catalysts

May 29, 2024, 1:52 PM EDT - 1 year ago

Genfit: Under The Radar Biotech With Upcoming Catalysts

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

May 22, 2024, 12:05 PM EDT - 1 year ago

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2024 Financial Information

May 14, 2024, 4:10 PM EDT - 1 year ago

GENFIT Reports First Quarter 2024 Financial Information

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Apr 25, 2024, 4:10 PM EDT - 2 years ago

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Apr 15, 2024, 4:10 PM EDT - 2 years ago

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Apr 5, 2024, 2:00 PM EDT - 2 years ago

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Apr 4, 2024, 4:10 PM EDT - 2 years ago

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Feb 29, 2024, 4:10 PM EST - 2 years ago

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Rickycello
Rickycello Feb. 25 at 12:10 PM
$GNFT bear: 6.78€ base: 10.26€ bull: 15€ Intrinsic value: 3.93€ Sell price target: 10.51€ (12% margin) Reward / risk: 0.39 Risk / reward: 2.54
0 · Reply
Alexis348
Alexis348 Feb. 24 at 6:33 PM
$GNFT what's everyones thought on this. How far up can it go?!
0 · Reply
RunnerSignals
RunnerSignals Feb. 24 at 3:04 PM
Top Stocks Hitting 52-Week High $AXTI $IPG $GNFT $TSM $FRO
0 · Reply
Noobnr1
Noobnr1 Feb. 20 at 12:49 PM
$GNFT 🚀🚀🚀
0 · Reply
FloatSearcher
FloatSearcher Feb. 18 at 9:32 AM
$GNFT Oncology biotech where trial design credibility matters.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 11:31 AM
$GNFT RSI: 54.52, MACD: 0.2324 Vol: 0.24, MA20: 6.04, MA50: 5.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ThunderTheater
ThunderTheater Dec. 26 at 5:29 PM
$GNFT Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Execution quality will determine whether momentum is sustainable.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 11:50 AM
$GNFT Current Stock Price: $0.00
0 · Reply
QuestCube
QuestCube Dec. 26 at 5:35 AM
$GNFT Upside exists, but only alongside disciplined prioritization and resource control. Cash generation will determine how self-sustaining growth becomes. If milestones track on schedule, sentiment can re-rate faster than fundamentals. Future returns will be dictated by execution quality, not headlines.
0 · Reply
judgeyoung2
judgeyoung2 Dec. 3 at 4:29 PM
$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.
0 · Reply
TwongStocks
TwongStocks Nov. 20 at 5:03 PM
$GNFT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market https://ir.genfit.com/news-releases/news-release-details/genfit-announces-effectiveness-voluntary-delisting-american
0 · Reply
Doozio
Doozio Nov. 20 at 2:36 AM
$GNFT 🐒🍌🧠⏰♾️
0 · Reply
BLD33
BLD33 Nov. 11 at 3:24 PM
$GNFT 9 days of covering !!!
0 · Reply
twincam
twincam Nov. 10 at 11:29 PM
$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.
0 · Reply
Noobnr1
Noobnr1 Nov. 10 at 5:47 PM
$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:56 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-enters-research-collaboration-everzom-advance-exosome
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:55 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-presents-promising-new-preclinical-data-ntzg1090n
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 3 at 1:27 PM
$GNFT Current Stock Price: $3.85 No options data available.
0 · Reply
Rickycello
Rickycello Oct. 28 at 9:45 PM
$GNFT !!! Mark the day!!! "...announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025."
0 · Reply
abbk
abbk Oct. 24 at 4:42 PM
$GNFT not trading? no movement
0 · Reply
Amb8675309
Amb8675309 Oct. 9 at 5:36 PM
$GNFT what’s with the “new orders not being accepted at this time” message
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 3:49 PM
$GNFT Brilliant piece that captures GNFT's situation perfectly. So if you want to update your understanding of GNFT or get to know GNFT better, this is essential reading. https://beyondspx.com/quote/GNFT/analysis/genfit-s-strategic-reorientation-unlocking-value-in-liver-diseases-and-diagnostics-nasdaq-gnft
0 · Reply